Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Portfolio Pulse from Vandana Singh
Gilead Sciences Inc and Arcus Biosciences Inc announced positive preliminary results from their ongoing Phase 2 EDGE-Gastric study. The study evaluates the safety and efficacy of a combination cancer therapy involving domvanalimab, zimberelimab, and chemotherapy in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma. The therapy showed encouraging overall response rate and six-month progression-free survival rate. The companies also have three ongoing Phase 3 studies of domvanalimab-containing regimens in lung cancer.

November 07, 2023 | 4:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead's ongoing Phase 2 study with Arcus Biosciences shows promising results, which could potentially boost its stock.
Positive clinical trial results often lead to increased investor confidence, potentially driving the stock price up.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Arcus Biosciences' collaboration with Gilead in the ongoing Phase 2 study shows encouraging results, which could positively impact its stock.
Positive clinical trial results often lead to increased investor confidence, potentially driving the stock price up.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80